Inventor · disambiguated record
Chengyuan Lu
Also filed as: LU CHENGYUAN
10 granted patents·10 pending applications·5 citations·filing 2019–2024
81Inventor score
Top patents by PatentIndex Score
20 records- 0189US10934365B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Mar 2, 2021·2 cites·25 claims
- 0288US11352429B2Anti-PD-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Granted Jun 7, 2022·1 cites·26 claims
- 0385US11142582B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Oct 12, 2021·1 cites·14 claims
- 0482US11034764B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Jun 15, 2021·1 cites·18 claims
- 0581US2025129164A1Anti-pd-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
- 0680US2025034271A1Anti-cd40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0780US2025034256A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0879US2024343806A1Anti-ctla4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0978US2024352141A1Anti-ox40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1077US2024092922A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1175US12180281B2Anti-PD-1 antibodies and methods of treating cancerBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted Dec 31, 2024·0 cites·30 claims
- 1272US12134653B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Nov 5, 2024·0 cites·16 claims
- 1370US2022251229A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1469US11292849B2Anti-TNFRSF9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Apr 5, 2022·0 cites·33 claims
- 1567US12054547B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
- 1667US11999790B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Jun 4, 2024·0 cites·17 claims
- 1767US2021403570A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1865US11155625B2Anti-PD-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·43 claims
- 1951US2022073621A1Anti-pd-l1 antibody and use thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
- 2044US2021269525A1ANTI-CD3e ANTIBODIES AND USES THEREOFBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →